問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Emergency Medicine

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間：2025-09-23

何肇基CHAO-CHI HO, CHAO-CHI HO
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

225Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何肇基

National Taiwan University Hospital

Division of Thoracic Medicine

List

59Cases

2022-10-28 - 2025-11-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2019-03-01 - 2025-12-31

Phase I

Completed
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

  • Test Drug

    TNO155

Participate Sites
1Sites

Recruiting1Sites

2024-05-01 - 2029-03-31

Phase III

Active
A Randomized, Double-blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

  • Condition/Disease

    Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    injection injection

Participate Sites
11Sites

Not yet recruiting10Sites

Recruiting1Sites

2015-11-01 - 2025-08-29

Phase III

Completed
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Nivolumab

Participate Sites
5Sites

Terminated5Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2009-05-01 - 2011-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-04-15 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-09-01 - 2008-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2010-08-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-03-01 - 2018-02-28

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB